Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of veliparib with carboplatin and paclitaxel in BRCA-associated HER2-negative advanced breast cancer
MOH_2017-03-29_000120Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Veliparib + carboplatin + paclitaxel with Placebo + carboplatin + paclitaxel (2 arms). Primary endpoint: progression-free survival. Started Oct 2014; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-03-29_000120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-29_000120.